Over the next five years, the projection is that genomics is going to explode.
Genomics is the study of our DNA.
The cost of having your genome sequenced has dropped from billions to thousands of dollars – and will probably be as low as $100 in the near future.
This is significant. For one thing, the reduced cost has led to insurance companies starting to pay for patients to have clinical grade DNA tests, in the hopes of catching disease in its earliest stages.
Over the next five years, ARK Invest believes that the number of genomes sequenced will rise from 1.5 million tested in 2018 to 100 million by 2023.
If that is the case, it should be very positive for companies that specialize in genomics.
Here are three companies you may want to look into:
- Illumina (NASDAQ: ILMN): Illumina is the most dominant company in the genomics field, because 90% of all genes sequenced in the world are done so by using their machines. They are single-handedly responsible for driving down the cost of sequencing a whole human genome from millions of dollars to under a thousand and on the road to ultimately below $100.
- Invitae (NYSE: NVTA): Invitae is a much smaller company. But it has its sights on becoming the “Amazon of genomics” by making it very easy and convenient for people to get comprehensive genetic testing done during their yearly doctor’s visit.
- Veracyte (NASDAQ: VCYT): Another up and coming small-cap company in genomics. Veracyte is a genomics diagnostic company. The company is transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis.
Over the next five years, genomes sequenced are projected to grow 85% annually.
I don’t know if that will come to fruition, but if it does…that’s incredible growth!
Click the image of the book at left to be taken to its Amazon page. (Disclosure: As a participant in the Amazon Services LLC Associates Program, I earn a small commission on each sale generated through these links.)